semaglutide + metformin

Semaglutide + metformin is a combination therapy used primarily for the management of type 2 diabetes. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of endogenous GLP-1, enhancing insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite. Metformin is a biguanide that decreases hepatic glucose production, improves insulin sensitivity in peripheral tissues, and reduces intestinal absorption of glucose. Together, these agents provide complementary mechanisms to improve glycemic control and promote weight loss in patients with type 2 diabetes. This combination has also been shown to improve lipid profiles and reduce cardiovascular risk factors[1][2][3][5].